RCE
$145M—
Recce Pharmaceuticals
Biotechnology · Infectious disease
Developing RECCE 327 synthetic anti-infective polymer for bacterial infections including sepsis and wound infections. Novel mechanism distinct from traditional antibiotics.
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.4M
Dec 2025 4C
Runway
—Based on Dec 2025 4C
Market Cap
$145M
Burn Rate
$4.7M/qtr
Dec 2025 4C
Shares Outstanding
289M
Pipeline Assets
1
Latest Insight(1)
27 Feb 2026Half YearAppendix 4D and Interim Financial Report
Cash$0.4M·Burn$9.5M/q·OCF$-9.5M
3M Price
RCE.ASX$0.500-23.1% 3M
Low $0.430High $0.660
Pipeline Assets (1)
RECCE 327Bacterial infections / sepsis
PreclinicalDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
RECCE 327
Bacterial infections / sepsis
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
3 transactionsLast 90dNo Activity
Buys0
Sells0
OPTIONS EXERCISEJames Grahamopen_in_new
2026-02-22
58d before · Positive Regulatory Inspection Outcome for Phase 3 Trial
OPTIONS EXERCISEDr John Prendergastopen_in_new
2026-02-22
58d before ·
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
25 competitor trialsPhase 2+ · Non-ASX
Bacterial Infections / Sepsis25 active trials
8 Ph411 Ph31 Ph2/34 Ph21 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (4)· 3 upcoming · 1 past
RECCE 327 Phase 3 DFI interim analysis (155 patients)
UpcomingExpectedarrow_upwardHigh30 June 2026
RECCE 327 Phase 3 DFI full enrollment (310 patients)
UpcomingExpectedarrow_upwardHigh31 Dec 2026
Indonesia BPOM conditional approval
UpcomingSpeculativearrow_upwardHigh31 Dec 2026
expand_more1 past catalyst
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 4 tracked
Completed catalysts
✓Positive Regulatory Inspection Outcome for Phase 3 Trial· readout — subject to clinical uncertainty— The Indonesian National Agency of Drug and Food Control (BPOM) completed a routine regulatory inspection of the Phase 3 trial site with no findings that prevent the study from continuing. Patient dosing is ongoing across five sites, with an interim data analysis planned at 155 patients completed. Regulatory approval in Indonesia is anticipated in CY2026.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.